Moscow Mayor Sergei Sobyanin announced the launch of new medicine production in the capital, as reported by the press service of the metropolitan mayor. In 2024, the turnover of the capital’s pharmaceutical sector increased by 43.8% year-on-year, reaching 606.3 billion rubles.
Moscow pharmaceutical companies will soon begin producing drugs based on monoclonal antibodies for the treatment of rheumatoid arthritis and osteoporosis, with the first shipments expected by the end of 2025 or early 2026. Additionally, production will include ready-made dosage forms for orphan diseases, with annual output projected at between 3.8 to 5.4 million vials for five INN, as well as anticancer drugs for seven INN.
Sobyanin’s press service noted that there are already more than 300 enterprises in the city that are continually increasing production volumes and expanding their product range, which facilitates the crucial task of providing the country’s residents with medicines and medical products.
With active support from the city, the production of medicines saw a 12.3% increase in January. The turnover of the capital’s pharmaceutical sector in 2024 reached 606.3 billion rubles, reflecting a 43.8% rise compared to 2023 at comparable prices.
In his annual report to the Moscow City Duma at the end of 2024, Sobyanin highlighted that almost 100% of prescriptions in Moscow are filled with the necessary drugs.
